Mortality in pacemaker-treated patients. A follow-up study of the impact of HLA B27 and associated rheumatic disorders.
The mortality in pacemaker-treated patients is due to underlying disorders, and is increased in patients with ischemic heart disease, congestive heart failure, diabetes and renal dysfunction. We have recently shown that the HLA B27-associated inflammatory disease process is the probable underlying cause in 15-20% of permanently paced men. Consequently, we undertook this study to evaluate any impact on mortality of HLA B27 and associated rheumatic disorders. The mortality among pacemaker patients was compared with that of the general population. Comparisons were also made between pacemaker patients with and without HLA B27 and associated disorders. We did not find any influence on mortality associated with the immunogenetic marker HLA B27 or with HLA B27-associated rheumatic disorders.
D000368:Aged; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000276:immunology; D005500:Follow-Up Studies; D005819:Genetic Markers; D006680:HLA Antigens / Q000032:analysis*; D015796:HLA-B27 Antigen; D006801:Humans; D008297:Male; D010138:Pacemaker, Artificial / Q000401:mortality*; D013167:Spondylitis, Ankylosing / Q000150:complications* / Q000276:immunology
D005819:Genetic Markers; D006680:HLA Antigens; D015796:HLA-B27 Antigen